FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281906358> ?p ?o ?g. }

• W4281906358 abstract "Clinical evidence indicates that the melanocortin peptide ACTH is effective in inducing remission of nephrotic glomerulopathies like minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS), including those resistant to steroids. This suggests that a steroid-independent melancortinergic mechanism may contribute. However, the type of melanocortin receptor (MCR) that conveys this beneficial effect as well as the underlying mechanisms remain controversial. Burgeoning evidence suggests that MC5R is expressed in glomeruli and may be involved in glomerular pathobiology. This study aims to test the effectiveness of a novel highly selective MC5R agonist (MC5R-A) in puromycin aminonucleoside (PAN) nephrosis. Upon PAN injury, rats developed evident proteinuria on day 5, denoting an established nephrotic glomerulopathy. Following vehicle treatment, proteinuria continued to persist on day 14 with prominent histologic signs of podocytopathy, marked by ultrastructural glomerular lesions, including extensive podocyte foot process effacement. Concomitantly, there was loss of podocyte homeostatic markers, such as synaptopodin and podocin, and de novo expression of the podocyte injury marker desmin. Treatment with MC5R-A attenuated urine protein excretion and mitigated the loss of podocyte marker proteins, resulting in improved podocyte ultrastructural changes. In vitro in cultured podocytes, MC5R-A prevented the PAN-induced disruption of actin cytoskeleton integrity and apoptosis. MC5R-A treatment in PAN-injured podocytes also reinstated inhibitory phosphorylation and thus averted hyperactivity of GSK3β, a convergent point of multiple podocytopathic pathways. Collectively, pharmacologic activation of MC5R by using the highly selective small-molecule agonist is likely a promising therapeutic strategy to improve proteinuria and glomerular injury in protenuric nephropathies." @default.
• W4281906358 created "2022-06-13" @default.
• W4281906358 creator A5007301131 @default.
• W4281906358 creator A5041867945 @default.
• W4281906358 creator A5066860889 @default.
• W4281906358 creator A5072191588 @default.
• W4281906358 creator A5085728336 @default.
• W4281906358 date "2022-06-01" @default.
• W4281906358 modified "2023-09-25" @default.
• W4281906358 title "Pharmacological Melanocortin 5 Receptor Activation Attenuates Glomerular Injury and Proteinuria in Rats With Puromycin Aminonucleoside Nephrosis" @default.
• W4281906358 cites W1543867390 @default.
• W4281906358 cites W1971097484 @default.
• W4281906358 cites W1979144815 @default.
• W4281906358 cites W1982530528 @default.
• W4281906358 cites W1986798594 @default.
• W4281906358 cites W2005462142 @default.
• W4281906358 cites W2005648142 @default.
• W4281906358 cites W2008367188 @default.
• W4281906358 cites W2020382755 @default.
• W4281906358 cites W2023116194 @default.
• W4281906358 cites W2029216719 @default.
• W4281906358 cites W2051190674 @default.
• W4281906358 cites W2077889744 @default.
• W4281906358 cites W2083712509 @default.
• W4281906358 cites W2093370492 @default.
• W4281906358 cites W2108151651 @default.
• W4281906358 cites W2169990586 @default.
• W4281906358 cites W2170590133 @default.
• W4281906358 cites W2232635222 @default.
• W4281906358 cites W2278023712 @default.
• W4281906358 cites W2279880775 @default.
• W4281906358 cites W2302857585 @default.
• W4281906358 cites W2330138071 @default.
• W4281906358 cites W2405545371 @default.
• W4281906358 cites W2407599512 @default.
• W4281906358 cites W2411410774 @default.
• W4281906358 cites W2416978640 @default.
• W4281906358 cites W2470993797 @default.
• W4281906358 cites W27385377 @default.
• W4281906358 cites W2890306542 @default.
• W4281906358 cites W2893308693 @default.
• W4281906358 cites W2897490362 @default.
• W4281906358 cites W2899433742 @default.
• W4281906358 cites W2954336018 @default.
• W4281906358 cites W3014844813 @default.
• W4281906358 cites W3033070385 @default.
• W4281906358 cites W3037589423 @default.
• W4281906358 cites W3182358672 @default.
• W4281906358 doi "https://doi.org/10.3389/fphys.2022.887641" @default.
• W4281906358 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35721571" @default.
• W4281906358 hasPublicationYear "2022" @default.
• W4281906358 type Work @default.
• W4281906358 citedByCount "1" @default.
• W4281906358 countsByYear W42819063582023 @default.
• W4281906358 crossrefType "journal-article" @default.
• W4281906358 hasAuthorship W4281906358A5007301131 @default.
• W4281906358 hasAuthorship W4281906358A5041867945 @default.
• W4281906358 hasAuthorship W4281906358A5066860889 @default.
• W4281906358 hasAuthorship W4281906358A5072191588 @default.
• W4281906358 hasAuthorship W4281906358A5085728336 @default.
• W4281906358 hasBestOaLocation W42819063581 @default.
• W4281906358 hasConcept C126322002 @default.
• W4281906358 hasConcept C134018914 @default.
• W4281906358 hasConcept C153911025 @default.
• W4281906358 hasConcept C170493617 @default.
• W4281906358 hasConcept C2776855237 @default.
• W4281906358 hasConcept C2777146197 @default.
• W4281906358 hasConcept C2777747828 @default.
• W4281906358 hasConcept C2778415529 @default.
• W4281906358 hasConcept C2778930706 @default.
• W4281906358 hasConcept C2779200571 @default.
• W4281906358 hasConcept C2779561371 @default.
• W4281906358 hasConcept C2779993316 @default.
• W4281906358 hasConcept C2780091579 @default.
• W4281906358 hasConcept C2781156571 @default.
• W4281906358 hasConcept C2781175652 @default.
• W4281906358 hasConcept C2910727860 @default.
• W4281906358 hasConcept C3675279 @default.
• W4281906358 hasConcept C71924100 @default.
• W4281906358 hasConcept C86803240 @default.
• W4281906358 hasConceptScore W4281906358C126322002 @default.
• W4281906358 hasConceptScore W4281906358C134018914 @default.
• W4281906358 hasConceptScore W4281906358C153911025 @default.
• W4281906358 hasConceptScore W4281906358C170493617 @default.
• W4281906358 hasConceptScore W4281906358C2776855237 @default.
• W4281906358 hasConceptScore W4281906358C2777146197 @default.
• W4281906358 hasConceptScore W4281906358C2777747828 @default.
• W4281906358 hasConceptScore W4281906358C2778415529 @default.
• W4281906358 hasConceptScore W4281906358C2778930706 @default.
• W4281906358 hasConceptScore W4281906358C2779200571 @default.
• W4281906358 hasConceptScore W4281906358C2779561371 @default.
• W4281906358 hasConceptScore W4281906358C2779993316 @default.
• W4281906358 hasConceptScore W4281906358C2780091579 @default.
• W4281906358 hasConceptScore W4281906358C2781156571 @default.
• W4281906358 hasConceptScore W4281906358C2781175652 @default.
• W4281906358 hasConceptScore W4281906358C2910727860 @default.
• W4281906358 hasConceptScore W4281906358C3675279 @default.
• W4281906358 hasConceptScore W4281906358C71924100 @default.
• W4281906358 hasConceptScore W4281906358C86803240 @default.
• W4281906358 hasFunder F4320332161 @default.

• next